Small dense LDL cholesterol is a robust therapeutic marker of statin treatment in patients with acute coronary syndrome and metabolic syndrome

2011 ◽  
Vol 412 (15-16) ◽  
pp. 1423-1427 ◽  
Author(s):  
Yoshifumi Fukushima ◽  
Satoshi Hirayama ◽  
Tsuyoshi Ueno ◽  
Tomotaka Dohi ◽  
Tetsuro Miyazaki ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Acute Coronary Syndrome ◽  
Ldl Cholesterol ◽  
Statin Treatment ◽  
Small Dense Ldl ◽  
Coronary Syndrome

scholarly journals Triglyceride and Small Dense LDL-Cholesterol in Patients with Acute Coronary Syndrome

2021 ◽  
Vol 10 (19) ◽  
pp. 4607
Author(s):  
Masakazu Hori ◽  
Teruhiko Imamura ◽  
Nikhil Narang ◽  
Hiroshi Onoda ◽  
Shuhei Tanaka ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Acute Coronary Syndrome ◽  
Body Mass ◽  
Triglyceride Level ◽  
Ldl Cholesterol ◽  
High Body Mass Index ◽  
Daily Practice ◽  
Serum Samples ◽  
Small Dense Ldl ◽  
Coronary Syndrome

Background: Small dense LDL-cholesterol is an established risk factor for atherosclerosis but is not routinely measured in daily practice. The association between small dense LDL-cholesterol and triglyceride, which in turn is routinely measured, in patients with acute coronary syndrome remains unknown. Methods: Consecutive patients with acute coronary syndrome who were admitted to our institute were prospectively included, and serum samples were obtained on admission. The association between small dense LDL-cholesterol and triglyceride was investigated. Results: Among 55 patients (median 71 years old, 64% men), median (interquartile range) small dense LDL-cholesterol was 23.6 (17.0, 36.0) and triglyceride was 101 (60, 134) mg/dL. Triglyceride level correlated with small dense LDL-cholesterol (r = 0.67, p < 0.001) and was an independent determinant of small dense LDL-cholesterol together with body mass index (p = 0.010 and p = 0.008, respectively). Those with high triglyceride and high body mass index had a 3-fold level of small dense LDL-cholesterol compared with those with low triglyceride and low body mass index (45.8 [35.0, 54.0] mg/dL versus 15.0 [11.6, 23.7] mg/dL, p = 0.001). Conclusions: Triglyceride level was a major determinant of small dense LDL-cholesterol in patients with acute coronary syndrome. Triglyceride level might be a useful and practical biomarker for risk stratification for patients with acute coronary syndrome together with body mass index.

Statin Treatment and Prognosis of Elderly Patients Discharged after Non-ST Segment Elevation Acute Coronary Syndrome

Cardiology ◽  
2019 ◽  
Vol 143 (1-2) ◽  
pp. 14-21 ◽  
Author(s):  
Lourdes Vicent ◽  
Albert Ariza-Solé ◽  
Pablo Díez-Villanueva ◽  
Oriol Alegre ◽  
Juan Sanchís ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Elderly Patients ◽  
Ldl Cholesterol ◽  
Statin Treatment ◽  
Invasive Approach ◽  
St Segment Elevation ◽  
Coronary Syndrome ◽  
Cholesterol Levels ◽  
St Segment ◽  
Elevation Acute Coronary Syndrome

Background: Statins are recommended for secondary prevention. Our aims were to describe the proportion of very elderly patients receiving statins after non-ST segment elevation acute coronary syndrome (NST-ACS) and to determine the prognostic implications of statins use. Methods: This prospective registry was performed in 44 hospitals that included patients ≥80 years discharged after a NST-ACS from April 2016 to September 2016. Results: We included 523 patients, the mean age was 84.2 ± 4.0 years and 200 patients (38.2%) were women. Previous statin treatment was recorded in 282 patients (53.4%), and 135 (32.5%) had LDL cholesterol levels >2.6 mmol/L. Mean LDL cholesterol levels during admission were 2.3 ± 0.9 mmol/L. Statins were prescribed at discharge to 474 patients (90.6%). Compared with patients discharged on statins, those that did not receive statins were more often frail (22 [47.8%] vs. 114 [24.4%], p < 0.01) and underwent an invasive approach less frequently (30 [61.2%] vs. 374 [78.9%], p = 0.01). During a 6-month follow-up, 50 patients died (9.5%). There was a nonsignificant trend to higher mortality in patients not treated with statins (6 [15%] vs. 44 [9.6%], p = 0.30), but statins were not independently associated with lower mortality (hazard ratio [HR] 0.79; 95% confidence interval [CI] 0.30–2.11, p = 0.65), nor with a reduction in the combined endpoint mortality/hospitalizations (HR 0.89; 95% CI 0.52–1.55, p = 0.69). Conclusions: Although most octogenarians presenting a NST-ACS are already on statins before the episode, their LDL cholesterol is frequently >2.6 mmol/L. Octogenarians who do not receive statins have a high-risk profile, with significant frailty and comorbidity.

scholarly journals Influence of Fatty Liver on Plasma Small, Dense LDL- Cholesterol in Subjects with and without Metabolic Syndrome

2011 ◽  
Vol 18 (1) ◽  
pp. 1-7 ◽  
Author(s):  
Ikumi Sugino ◽  
Koji Kuboki ◽  
Tomoko Matsumoto ◽  
Eiichi Murakami ◽  
Chiaki Nishimura ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Fatty Liver ◽  
Ldl Cholesterol ◽  
Small Dense Ldl

scholarly journals Clinical Utility of Small Dense LDL Cholesterol in Metabolic Syndrome

2017 ◽  
Vol 08 (09) ◽  
Author(s):  
Wahid Ali ◽  
Mukesh Kumar ◽  
Kauser Usman ◽  
Mohd Tasleem ◽  
Mohd Wamique
Keyword(s):  
Metabolic Syndrome ◽  
Clinical Utility ◽  
Ldl Cholesterol ◽  
Small Dense Ldl

scholarly journals Influence of metabolic syndrome and gender on heart failure following acute coronary syndrome

2014 ◽  
Vol 9 (9-10) ◽  
pp. 344-345
Author(s):  
Darko Kranjcec ◽  
Mijo Bergovec ◽  
Miroslav Raguz
Keyword(s):  
Heart Failure ◽  
Metabolic Syndrome ◽  
Acute Coronary Syndrome ◽  
Coronary Syndrome ◽  
And Gender

Abstract 14134: Effects of Statin Plus Ezetimibe versus Statin Alone on Coronary Atherosclerosis in Acute Coronary Syndrome

Circulation ◽  
2015 ◽  
Vol 132 (suppl_3) ◽  
Author(s):  
Kiyoshi Hibi ◽  
Kazuo Kimura ◽  
Shinjo Sonoda ◽  
Yutaka Otsuji ◽  
Toyoaki Murohara ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Combination Therapy ◽  
Therapy Group ◽  
Combined Therapy ◽  
Coronary Plaque ◽  
Statin Treatment ◽  
Combination Therapy Group ◽  
Plaque Volume ◽  
Coronary Syndrome ◽  
Percent Change

Introduction: IMPROVE-IT trial showed that ezetimibe plus statin treatment, as compared with statin alone, decreased cardiovascular events in patients with acute coronary syndrome (ACS). However, proir studies have failed to show a beneficial effect of ezetimibe on carotid plaque progression when added to statin treatment. Hypothesis: The addition of ezetimibe to statin therapy affects coronary plaque behavior in the non-culprit vessel. Methods: We conducted a prospective, randomized open-label parallel group study with blind endpoint evaluation conducted at 10 centers in Japan. A total of 128 statin naïve patients with ACS undergoing intravascular ultrasound (IVUS) guided percutaneous coronary intervention were randomized and nonculprit coronary lesions associated with mild-to-moderate stenosis in 103 patients had evaluable IVUS examinations at baseline and at 8 to 12 months follow-up. Conventional IVUS and integrated backscatter (IB)-IVUS measurements at 1-mm intervals were calculated. Patients were randomly assigned to receive either 2mg/day of pitavastatin plus 10mg/day ezetimibe or 2mg/day of pitavastatin. Primary endpoints were the percentage change in non-culprit coronary plaque volume and percent change in lipid plaque volume. Results: Mean low density lipoprotein cholesterol was reduced from 125mg/dl to 65mg/dl in the combination therapy group receiving statin plus ezetimibe (n=50) and 126mg/dl to 87 mg/dl in the statin alone group (n=53)(between group difference of 16.9%, P<0.0001). Length of analyzed segment did not differ between the groups (median 38.0 vs. 41.2 mm, p=0.40). The primary endpoint, percent change in plaque volume, was -5.1% in the combination therapy group and -6.2% in the statin alone group (P=0.66), although both groups resulted in reduction of plaque volume compared with baseline (both p=0.001). The percent change in lipid plaque volume did not differ between the groups (4.3 vs. -3.0%, P=0.37). Conclusions: Among patients with acute coronary syndrome, combined therapy with ezetimibe and statin did not result in a significant change in coronary plaque regression or tissue component compared with statin alone.

Sign in / Sign up

Export Citation Format

Share Document